Compare Stocks: GNPX, LGVN, OSRH, and MTVA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GNPX Genprex	$2.63 +2.7%	$4.05	$2.53 ▼ $1,210.00	$2.16M	-0.99	223,673 shs	118,554 shs
LGVN Longeveron	$2.58 -0.4%	$6.05	$2.30 ▼ $12.30	$8.23M	-0.19	180,920 shs	20,770 shs
MTVA MetaVia	$1.54	$1.58	$0.97 ▼ $14.85	$7.95M	0.96	85,225 shs	61,412 shs
OSRH OSR	$0.24 -2.8%	$0.30	$0.08 ▼ $0.91	$8.43M	0.48	5.91 million shs	38,787 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GNPX Genprex	0.00%	-20.06%	-23.10%	-79.25%	-98.65%
LGVN Longeveron	0.00%	-8.19%	-60.79%	-62.64%	-65.25%
MTVA MetaVia	0.00%	-7.23%	-16.30%	+4.05%	-86.41%
OSRH OSR	0.00%	+6.67%	-2.04%	-25.14%	-57.89%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GNPX Genprex	$2.63 +2.7%	$4.05	$2.53 ▼ $1,210.00	$2.16M	-0.99	223,673 shs	118,554 shs
LGVN Longeveron	$2.58 -0.4%	$6.05	$2.30 ▼ $12.30	$8.23M	-0.19	180,920 shs	20,770 shs
MTVA MetaVia	$1.54	$1.58	$0.97 ▼ $14.85	$7.95M	0.96	85,225 shs	61,412 shs
OSRH OSR	$0.24 -2.8%	$0.30	$0.08 ▼ $0.91	$8.43M	0.48	5.91 million shs	38,787 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GNPX Genprex	0.00%	-20.06%	-23.10%	-79.25%	-98.65%
LGVN Longeveron	0.00%	-8.19%	-60.79%	-62.64%	-65.25%
MTVA MetaVia	0.00%	-7.23%	-16.30%	+4.05%	-86.41%
OSRH OSR	0.00%	+6.67%	-2.04%	-25.14%	-57.89%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GNPX Genprex	1.00	Sell	N/A	N/A
LGVN Longeveron	2.00	Hold	$80.00	3,000.78% Upside
MTVA MetaVia	2.00	Hold	$20.00	1,198.70% Upside
OSRH OSR	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest GNPX, LGVN, OSRH, and MTVA Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/8/2026	LGVN Longeveron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/25/2026	LGVN Longeveron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	LGVN Longeveron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	LGVN Longeveron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/21/2026	MTVA MetaVia	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	GNPX Genprex	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/10/2026	MTVA MetaVia	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/9/2026	LGVN Longeveron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 10/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GNPX Genprex	N/A	N/A	N/A	N/A	$53.16 per share	N/A
LGVN Longeveron	$1.20M	6.86	N/A	N/A	$2.47 per share	1.04
MTVA MetaVia	N/A	N/A	N/A	N/A	$2.31 per share	N/A
OSRH OSR	$1.81M	4.66	N/A	N/A	$3.56 per share	0.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GNPX Genprex	-$16.23M	-$133.36	N/A	N/A	N/A	N/A	-163.12%	-128.98%	12/2/2026 (Estimated)
LGVN Longeveron	-$22.70M	-$9.90	N/A	N/A	N/A	-1,977.59%	-223.19%	-150.20%	11/3/2026 (Estimated)
MTVA MetaVia	-$12.97M	-$3.23	N/A	N/A	N/A	N/A	-209.67%	-107.91%	11/5/2026 (Estimated)
OSRH OSR	-$27.06M	-$0.37	N/A	N/A	N/A	-593.15%	-8.36%	-6.24%	N/A

Latest GNPX, LGVN, OSRH, and MTVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	GNPX Genprex	N/A	-$9.40	N/A	-$9.40	N/A	N/A
8/14/2026	Q2 2026	OSRH OSR	N/A	-$0.02	N/A	-$0.02	N/A	$0.32 million
8/12/2026	Q2 2026	LGVN Longeveron	-$1.75	-$0.19	+$1.56	-$1.90	$0.33 million	$0.29 million
8/6/2026	Q2 2026	MTVA MetaVia	-$0.82	-$0.90	-$0.08	-$0.90	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GNPX Genprex	N/A	N/A	N/A	N/A	N/A
LGVN Longeveron	N/A	N/A	N/A	N/A	N/A
MTVA MetaVia	N/A	N/A	N/A	N/A	N/A
OSRH OSR	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GNPX Genprex	N/A	6.76	6.76
LGVN Longeveron	N/A	2.63	2.63
MTVA MetaVia	N/A	2.06	2.06
OSRH OSR	N/A	0.18	0.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GNPX Genprex	14.05%
LGVN Longeveron	10.01%
MTVA MetaVia	1.37%
OSRH OSR	55.30%

Insider Ownership

Company	Insider Ownership
GNPX Genprex	0.25%
LGVN Longeveron	7.42%
MTVA MetaVia	0.60%
OSRH OSR	36.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GNPX Genprex	13	820,000	818,000	No Data
LGVN Longeveron	38	3.19 million	2.95 million	Not Optionable
MTVA MetaVia	8	5.16 million	5.13 million	N/A
OSRH OSR	N/A	35.12 million	22.16 million	N/A

GNPX, LGVN, OSRH, and MTVA Headlines

Recent News About These Companies

Emerging Growth Research Issues Company-Sponsored Research Flash Report on OSR Health, Inc.

August 27, 2026 | accessnewswire.comA

OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission

August 21, 2026 | accessnewswire.comA

OSR Health, Inc.: OSR Health Receives Nasdaq Staff Delisting Determination and Intends to Request Hearings Panel Appeal

August 20, 2026 | finanznachrichten.de

OSR Health Receives Nasdaq Staff Delisting Determination and Intends to Request Hearings Panel Appeal

August 19, 2026 | accessnewswire.comA

OSR Health, Inc.: OSR Health Sees Global Shareholder Momentum at Critical Inflection Point

August 19, 2026 | finanznachrichten.de

OSR Health Sees Global Shareholder Momentum at Critical Inflection Point

August 19, 2026 | accessnewswire.comA

OSR Holdings Stock Price History

August 18, 2026 | investing.com

OSR Health Inc (OSRH) Stock Price, Quote, News & History

August 11, 2026 | benzinga.com

OSR Health, Inc.: OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development

August 11, 2026 | finanznachrichten.de

OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development

August 11, 2026 | accessnewswire.comA

OSR Health Inc.

August 9, 2026 | marketwatch.com

OSRH OSR Health, Inc.

August 7, 2026 | seekingalpha.com

OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program

August 7, 2026 | accessnewswire.comA

Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Targeted Cancer Vaccine Platform

August 3, 2026 | accessnewswire.comA

OSR Health, Inc.: OSR Health Secures Nasdaq Communication: Loyalty CVR Program Will Not Trigger a Price Adjustment

August 1, 2026 | finanznachrichten.de

OSR Health Secures Nasdaq Communication: Loyalty CVR Program Will Not Trigger a Price Adjustment

July 31, 2026 | accessnewswire.comA

OSR Health, A Message From the CEO

July 13, 2026 | accessnewswire.comA

OSR Health Earnings Estimates, EPS & Revenue | NASDAQ:OSRH

July 6, 2026 | benzinga.com

CORRECTION FROM SOURCE: Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target

July 2, 2026 | finance.yahoo.com

Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target

July 2, 2026 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNPX, LGVN, OSRH, and MTVA Company Descriptions

Genprex NASDAQ:GNPX

$2.63 +0.07 (+2.73%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$2.64 +0.00 (+0.19%)

As of 10/2/2026 07:55 PM Eastern

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Longeveron NASDAQ:LGVN

$2.58 -0.01 (-0.39%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$2.56 -0.02 (-0.58%)

As of 10/2/2026 07:30 PM Eastern

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

MetaVia NASDAQ:MTVA

$1.54 0.00 (0.00%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.55 +0.01 (+0.78%)

As of 10/2/2026 07:58 PM Eastern

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.

OSR NASDAQ:OSRH

$0.24 -0.01 (-2.83%)

As of 10/2/2026 03:59 PM Eastern

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GNPX, LGVN, OSRH, and MTVA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GNPX, LGVN, OSRH, and MTVA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GNPX, LGVN, OSRH, and MTVA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNPX, LGVN, OSRH, and MTVA Company Descriptions

Genprex NASDAQ:GNPX

Longeveron NASDAQ:LGVN

MetaVia NASDAQ:MTVA

OSR NASDAQ:OSRH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GNPX, LGVN, OSRH, and MTVA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GNPX, LGVN, OSRH, and MTVA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GNPX, LGVN, OSRH, and MTVA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNPX, LGVN, OSRH, and MTVA Company Descriptions

Genprex NASDAQ:GNPX

Longeveron NASDAQ:LGVN

MetaVia NASDAQ:MTVA

OSR NASDAQ:OSRH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools